[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-women\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-women":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,69,94,121,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100626732","tumour-cell-response-to-acute-aerobic-exercise-in-breast-cancer-survivors-modulatory-effects-of-exercise-type-and-intensity-100626732",false,"NCT07439458","Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity","Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity (TCReX) No: RSU\u002FLSPA-PA-2024\u002F1-0004 is Financed by the Investment of the European Union Recovery and Resilience Facility and the State Budget Within the Project \"RSU Internal and RSU With LASE External Consolidation\" No. 5.2.1.1.i.0\u002F2\u002F24\u002FI\u002FCFLA\u002F005.","TCReX","Inclusion Criteria (intervention group):\n\n* Reproductive age (premenopausal);\n* Diagnosis of Stage II-III Triple-Negative Breast Cancer (TNBC) (negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2));\n* Timeframe of 3 to 9 months after completion of surgery, adjuvant chemotherapy, radiation therapy, and\u002For immunotherapy;\n* Physician-certified (cardiologist) physical fitness for exercise testing, supported by echocardiography (ECHO).\n\nInclusion Criteria (control group):\n\n* Reproductive age (premenopausal);\n* No current or prior diagnosis of any type of cancer;\n* Matched by age, body constitution, and physical fitness to the breast cancer participant group.\n\nExclusion Criteria:\n\n* Pregnancy;\n* Autoimmune diseases (e.g., thyroiditis, inflammatory bowel disease, atopic dermatitis, etc.);\n* Endocrine disorders (e.g., metabolic syndrome, diabetes);\n* Cardiovascular diseases;\n* Diagnosis of any other type of oncological disease;\n* Any condition for which physical activity is contraindicated (e.g., asthma, COPD, spinal disc herniation, severe iron deficiency anemia).",true,"FEMALE","35 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Cancer has emerged as a prominent cause of mortality in the 21st century, with breast cancer (BC) being the most diagnosed malignancy. Multidisciplinary cancer management has improved survival chances, but side effects and long-term consequences of treatments have significant implications for cancer survivors' health-related quality of life. Exercise is increasingly considered and used in cancer treatment and follow-up. However, studies demonstrating the biological mechanisms underlying the anticarcinogenic effects (ACE) of exercise are insufficient to justify the most appropriate physical activity for different clinical scenarios. Achieving scientific excellence in understanding the ACE of exercise in cancer management is critical to optimize treatment and enhance patients' quality of life.",[28,29,30,31,32],"Acute Exercise","Breast Cancer Cell Lines","Breast Cancer Survivors","Healthy Women","Myokine Response","RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-14","ACTUAL",{"date":39,"type":37},"2024-04-01",{"date":41,"type":22},"2026-09-30",{"name":43,"class":44},"Riga Stradins University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100634325","the-effectiveness-of-motivational-interviewing-in-preventing-early-childhood-caries-among-mothers-of-infants-in-terengganu-100634325","NCT07538219","The Effectiveness of Motivational Interviewing in Preventing Early Childhood Caries Among Mothers of Infants in Terengganu.","The Effectiveness of Motivational Interviewing in Preventing Early Childhood Caries: A Cluster Randomised Controlled Trial Among Mothers of Infants in Terengganu.","Inclusion Criteria:\n\n* Mothers:\n\n  * Malaysian citizens\n  * Can read and understand Bahasa Malaysia\n  * Aged 18 years old and above\n* Infants:\n\n  * Aged 6 months old (with or without erupted teeth)\n  * Born full-term (≥37 weeks of gestation)\n  * Without diagnosed congenital anomalies or syndromes\n\nExclusion Criteria:\n\n* Mothers\n\n  o Mothers experiencing postpartum depression or other significant postnatal issues\n* Infants\n\n  * Diagnosed with special needs, chronic diseases, or developmental defects\n  * Infants who are at risk for oral health problems due to pre-existing medical conditions\n  * Infants requiring specialized oral healthcare, such as those with cleft lip and palate, enamel hypoplasia","18 Years",{"count":55,"type":22},228,[25],"This study will be conducted in Ministry of Health (MOH) Maternal and Child Health Clinics (MCHCs) and MOH dental clinics in Setiu and Hulu Terengganu, selected for their similar sociodemographic characteristics. A two-arm, parallel cluster-randomized controlled trial (1:1 allocation) will be implemented, where the study group receives Anticipatory Guidance (AG) through Motivational Interviewing (MI), and the control group receives conventional MOH AG.\n\nMothers aged ≥18 years who can understand Bahasa Malaysia and their healthy 6-month-old infants (full-term, without congenital conditions) are eligible. Mothers with postpartum depression and infants requiring special oral healthcare are excluded. A total of 228 mother-infant pairs will be recruited using multistage sampling. Three MCHCs from Setiu and three randomly selected MCHCs from Hulu Terengganu will participate. Systematic sampling will be applied within each clinic.\n\nData collection occurs at infant ages 6, 9, and 12 months during routine immunization visits. At each visit, infants undergo oral examination using ICDAS and a caries risk assessment. Mothers complete age-specific validated questionnaires on knowledge and practices. The study group receives two MI sessions (at 6 and 9 months) with follow-up phone calls, while the control group receives routine AG by MOH staff.\n\nThe MI protocol will be developed based on established MI frameworks and be validated through expert review, will be pretested among mothers and dental officers\u002Ftherapists in MOH MCHC and MOH dental clinic in Besut district. While fidelity assessment of MI sessions conducted will be done using MITI 4.2.1 guidelines. All MI sessions will be delivered by the trained principal investigator. Approximately 8 minutes are required for infant oral examination, 7 minutes for questionnaire completion, and 30 minutes for MI.\n\nData will be analysed using descriptive statistics, paired t-tests, independent t-tests, McNemar's test, and Chi-Square test with significance set at p \\\u003C 0.05.\n\nEthical approval was obtained from Jawatankuasa Etika Penyelidikan Manusia USM (JEPeM)\u002F Human Research Ethics Committee USM (HREC) and Medical Research and Ethics Committee (MREC) MOH. Participation is voluntary, with confidentiality ensured. No major risks are expected.",[31,59],"Caries of Infancy","NOT_YET_RECRUITING","2026-04-12",{"date":63,"type":37},"2026-04-20",{"date":61,"type":22},{"date":66,"type":22},"2026-11-30",{"name":68,"class":44},"Universiti Sains Malaysia",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":17,"sex":18,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":45},"100633429","glow-study-effects-of-triple-protein-in-women-100633429","NCT07526571","GLOW Study: Effects of Triple Protein in Women","GLOW Study: A Randomized Trial to Evaluate the Effects of Triple Support Protein on Glucose, Lifestyle, and Overall Well-being in Women","Inclusion Criteria:\n\n* Females aged 30-60 years.\n* BMI 18.5-40 kg\u002Fm\\^2.\n* Recreationally active (≥30 min\u002Fwk moderate intensity exercise).\n* Healthy and free from disease per health history questionnaire.\n* Willing to abstain from caffeine, tobacco, and alcohol for 24 hours before testing days.\n\nExclusion Criteria:\n\n* Currently supplementing whey protein.\n* Pregnant or nursing.\n* Lactose intolerant.\n* Currently using creatine monohydrate.\n* Severe hearing or speech impairment or inability to speak English","30 Years","60 Years",{"count":21,"type":22},[25],"This single-site, randomized, blinded, placebo-controlled study will evaluate whether 4 weeks of daily Triple Support Protein powder improves glycemic control and overall well-being in healthy women aged 30-60 years. Participants will undergo baseline testing (DXA, fasting blood, standardized meal test with 2-hour glucose and insulin sampling), complete one acute supervised dose, and then consume a daily supplement for 4 weeks. During the final 14 days, participants will wear a continuous glucose monitor. Outcomes include postprandial glucose AUC, insulin sensitivity, and body composition.",[31],[83,84],"perimenopause","protein supplement","2026-04-06",{"date":87,"type":37},"2026-04-13",{"date":89,"type":22},"2026-04",{"date":91,"type":22},"2026-12-01",{"name":93,"class":44},"University of North Carolina, Chapel Hill",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100573433","effect-of-physical-activity-andor-probiotics-on-body-composition-and-physiological-parameters-in-women-100573433","NCT06746220","Effect of Physical Activity and\u002For Probiotics on Body Composition and Physiological Parameters in Women","AP-Pro-Fem","Inclusion Criteria:\n\n1. Being female\n2. Age ≥ 18 years old\n3. Have a BMI between 18.5 and 30 kg\u002Fm2\n4. Be registered as a student at the University of Orléans\n5. Be non-athletic\n6. Have no contraindication to the practice of physical activity\n7. All participants must sign informed consent before the start of the study\n\nExclusion Criteria:\n\n1. Smokers \\>10 cigarettes per day\n2. Having treatment for a pathology at the time of inclusion\n3. Taking a probiotic supplement during the last month prior to inclusion\n4. Practice physical activity regularly (150 minutes\u002Fweek of moderate physical activity according to the WHO)\n5. Participant under guardianship or curators\n6. Pregnant or breastfeeding women\n7. Menopausal women\n8. Allergy to any excipient known to be present in the probiotic or placebo formulation",{"count":102,"type":22},120,[25],"This is a prospective, comparative, double-blind, randomized, monocentric study.\n\nThe objective of this project is to evaluate the effects on health of probiotic supplementation (PS) with or without physical activity (PA). Participants who meet the study criteria will be randomized into 4 groups: probiotic and physical activity group (A+), probiotic and non-physical activity group (A-), placebo and physical activity group (T+), placebo and non-physical activity group (T-).\n\nThe probiotics used are Lactibiane® Reference provided by Pileje Laboratory. The study population are healthy women (university students) who do not practice sports. A total of 120 participants will participate.\n\nAt inclusion, each participant will undergo a medical examination, collect microbiota and salivary samples and perform different tests (questionnaires, assessments of strength and endurance). Then, a follow up phase will last 6 weeks. Each participant will receive a pillbox containing capsules (probiotic or placebo in a double-blind manner). Participants which randomized in the PA groups (A+ and A-) will perform 2 physical activity sessions per week for 6 weeks. At the end of this follow up phase, tests conducting during inclusion will be performed again.",[31],[107,108,109,110,111],"Microbiota","Probiotics","Physical activity","Health","women","2025-12-22",{"date":114,"type":37},"2025-12-30",{"date":116,"type":37},"2024-09-16",{"date":118,"type":22},"2027-12-15",{"name":120,"class":44},"Centre Hospitalier Régional d'Orléans",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":19,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100610026","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-subcutaneous-levonorgestrel-butanoate-for-female-contraception-100610026","NCT07222228","A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception","A Phase 2b Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception","Inclusion Criteria:\n\n1. Participant understands and signs an ICF approved by the institutional review board prior to any screening activities.\n2. Female and 18 to 35 years of age, inclusive, at enrollment (Visit 2, Day 1).\n3. Good general overall health with no chronic medical conditions that result in periodic exacerbations requiring significant medical care.\n4. Menstrual cycles of 21 to 35 days in length with typical variation in cycle length of 5 days or less when not using hormonal contraception.\n5. Intact uterus and at least 1 ovary.\n6. If used a hormonal contraceptive or intra-uterine device (IUD) prior to enrollment, the participant meets the appropriate criteria for time since last use:\n\n   1. Oral, transdermal, vaginal, copper or LNG IUD or implantable hormonal contraceptives: participants must have discontinued hormone use ≥4 days prior to start of study treatment, experienced bleeding that is consistent with menses in the opinion of the investigator and not have had unprotected intercourse since discontinuing the method.\n   2. Injectable contraception (e.g., DMPA): No injection during the 10 months prior to the Screening Visit, unless the participant has returned to normal menses (i.e., 2 consecutive menses) since last injection.\n7. Negative urine pregnancy test at enrollment (Visit 2, Day 1).\n8. Body mass index \\\u003C40 kg\u002Fm2.\n9. Willing to use the study method as the primary method of contraception until the end of the Treatment Period.\n10. At risk for pregnancy defined as:\n\n    1. Expecting to have ≥1 act of heterosexual intercourse each month during study participation until the end of the Treatment Period.\n    2. No medical history suggesting possible infertility or hypofertility, including but not limited to, ectopic pregnancy or pelvic infection (unless has had a subsequent intra-uterine pregnancy).\n    3. Has a sexual partner with no known problems with infertility orhypofertility.\n\nExclusion Criteria:\n\n1. Planning pregnancy during study participation through the End -of -Treatment Visit (Visit 11, Day 240).\n2. Is post-partum and has not had 2 spontaneous menses (1 cycle) since delivery or 1 menses since first or second trimester abortion or miscarriage.\n3. Breastfeeding or within 30 days of discontinuing breastfeeding unless the participant has already had 2 menses (1 cycle) following discontinuation of breastfeeding.\n4. Undiagnosed abnormal genital bleeding.\n5. Undiagnosed vaginal discharge, lesions, or abnormalities.\n6. Participating in another clinical study involving an IP or device within 30 days prior to the Screening Visit or planning to participate in another clinical study during this study.\n7. Not living in the catchment area of the study site.\n8. Known hypersensitivity or contraindication to progestins, including the active substance LB or any excipients of the study treatment.\n9. Current need for therapeutic anticoagulation or known history of thrombophilia.\n10. Use or planned use of exogenous reproductive hormones during study participation.\n11. Body weight change exceeding 10% over the previous year or planned significant weight loss during the study related to bariatric surgery, dieting, or planned treatment.\n12. Uncontrolled hypertension, in which diastolic blood pressure remains ≥95 mmHg or systolic blood pressure remains ≥145 mmHg.\n13. Smoking nicotine (e.g., cigarettes or electronic cigarettes) AND has at least 1 of the following comorbidities or conditions (at the discretion of the investigator):\n\n    * Current or history of venous thrombophlebitis or thromboembolic disorders (including deep vein thrombosis and pulmonary embolism).\n    * Current or history of cerebrovascular or coronary-artery disease.\n    * Valvular heart disease with thrombogenic complications.\n    * Diabetes with vascular involvement.\n    * Known inherited or acquired predisposition to venous thromboembolism or arterial thromboembolism (e.g., factor VLeiden, prothrombin mutation, antiphospholipid antibodies) or bruising within the last 12 months prior to consent.\n14. Current or past cerebrovascular or cardiovascular disease or at risk of clotting disorders.\n15. Impaired mobility (e.g., is wheelchair bound or bedridden) that, in the investigator's opinion, places the participant at increased risk of thrombosis.\n16. Known or suspected carcinoma of the breast or suspected progestin-dependent neoplasia.\n17. Known or suspected pelvic organ carcinoma.\n18. Known Papanicolaou (Pap) or human papillomavirus (HPV) test abnormality that would require a repeat evaluation or treatment during study participation based on standard of care guidelines (American Society for Colposcopy and Cervical Pathology or American College of Obstetricians and Gynecologists).\n19. Known benign or malignant liver tumors, renal disease, or active liver disease.\n20. Invasive cancer (past history of any carcinoma or sarcoma, except non-melanoma skin cancer) unless in remission for \\>5 years.\n21. Current or past medically diagnosed severe depression, which, in the investigator's opinion, could be exacerbated by use of a hormonal contraceptive, unless participant is on stable antidepressant medication.\n22. Known or suspected current alcohol dependence syndrome or any recreational drug use that may affect metabolism of the IP or study compliance.\n23. Abnormal screening laboratory values defined as:\n\n    1. Fasting clinical chemistry values or CBC values designated clinically significant by the investigator.\n    2. Liver function test results \\>twice the upper limit of normal.\n24. Uncontrolled thyroid disorder.",{"count":129,"type":22},165,[131],"PHASE2","This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception.",[31,134],"Female Contraception",[136],"Female contraception","2025-10-27",{"date":139,"type":37},"2025-10-29",{"date":141,"type":22},"2026-04-01",{"date":143,"type":22},"2029-03-31",{"name":145,"class":44},"Premier Research",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":45},"100591822","the-effect-of-the-menstrual-cycle-on-immune-cell-activity-and-recovery-after-resistance-exercise-100591822","NCT06985420","The Effect of the Menstrual Cycle on Immune Cell Activity and Recovery After Resistance Exercise","The Impact of the Menstrual Cycle on Innate Immune Cell Activation, Recruitment, and Adhesion Dynamics During Recovery From Damaging Resistance Exercise: Role of Neutrophils and Systemic Chemokines.","Inclusion Criteria:\n\n* Women between the ages of 18 and 40.\n* Must weigh at least 110 pounds.\n* Healthy as determined by medical history, physical activity readiness, and menstrual cycle questionnaires.\n* Actively resistance training for at least 6 months (minimum of 3 resistance training sessions per week, with at least one lower body session).\n* Pre-menopausal and have a regular menstrual cycle (eumenorrheic), with a clear start of menses (early follicular phase).\n* Not currently pregnant or planning to become pregnant during the study.\n* Have not used hormonal birth control or intrauterine devices in the past 3 months (or three full menstrual cycles).\n* Able to recall approximate start dates of their last 6 menstrual cycles.\n* Willing to follow study instructions, including avoiding exercise, alcohol, and caffeine before testing visits.\n* Free from previous or current lower body injuries that could limit performance.\n* Not regularly taking any medications that could interfere with the study.\n* Determined to have a high likelihood of successful blood draws by a certified phlebotomist.\n\nExclusion Criteria:\n\n* Do not give consent to participate.\n* Have been determined unfit to participate based on medical or activity history (using health questionnaires).\n* Currently take prescription or over-the-counter medication that could affect the study results.\n* Have a chronic illness requiring medical care.\n* Not currently resistance-trained (don't meet the exercise requirement).\n* Pregnant or planning to become pregnant during the study.\n* Do not have regular periods or have been diagnosed as amenorrhoeic (absence of menstruation).\n* Currently taking any performance-enhancing drugs.\n* Currently using hormonal birth control or intrauterine devices (IUDs), or have used them in the past three months (or three full menstrual cycles).\n* Determined unlikely to have a successful blood draw by a trained phlebotomist.\n* Weigh less than 110 pounds.","40 Years",{"count":21,"type":22},"OBSERVATIONAL","The goal of this observational study is to learn how the menstrual cycle affects immune cell activation, recruitment, and recovery responses after resistance exercise in healthy, resistance-trained women aged 18-40. The main questions it aims to answer are:\n\nDoes the menstrual cycle influence neutrophil recruitment and adhesion after resistance exercise? Does the menstrual cycle affect markers of muscle damage and functional recovery? Researchers will compare three menstrual phases (early follicular, late follicular, and mid-luteal) to see if immune responses and recovery outcomes differ across these phases.\n\nParticipants will:\n\nComplete resistance exercise protocols across three different menstrual cycle phases.\n\nProvide blood samples to assess immune cell activation and muscle damage markers.\n\nTrack sleep, mood, and recovery with questionnaires and wear an accelerometer.",[31,158,159],"Menstruation","Resistance Exercise","2025-05-14",{"date":162,"type":37},"2025-05-22",{"date":164,"type":37},"2024-08-16",{"date":166,"type":22},"2025-05",{"name":168,"class":44},"University of Central Florida"]